US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...

TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from ...

Medicare is undergoing sweeping changes in 2025, including a $2,000 limit on out-of-pocket Part D drug costs, the elimination ...

The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...

Many Part D prescription drug plans cover Trelegy Ellipta, but costs can vary by plan type and insurer. Read more.

GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...

The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...

Bengaluru: India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by ...

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a Profit After Tax of ₹229 crore, as announced on February 14.

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company stated.

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.